Skip to main content

Advertisement

SpringerLink
Log in

Revisiting the Natural History of Chronic HBV Infection

  • Hepatitis B (JK Lim, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Although effective vaccines have been available for more than three decades, hepatitis B virus (HBV) infection remains a global public health issue. It is estimated around 248 million people are chronically infected by HBV, and most of them are residing in the Asia-Pacific region. In HBV-endemic regions, the virus is primarily transmitted during the perinatal period or early childhood with an immature immune system, so it has a high rate of chronicity. Based on the virological and clinical manifestations, the natural course of chronic hepatitis B can be divided into four classical phases: immune tolerance, immune clearance, inactive carrier, and reactivation phases. The majority of patients will undergo spontaneous HBeAg seroconversion and enter an inactive carrier state. However, a small portion of patients may encounter intermittent or persistent hepatitis and eventually lead to severe adverse outcomes, such as liver cirrhosis, hepatic failure, or hepatocellular carcinoma. With recent advances in molecular and immunological technologies, several viral and host factors that may affect the clinical outcomes of chronic HBV infection have been identified. By integration of these emerging serological and viral biomarkers, the natural history of chronic HBV infection should be revisited. In conclusion, accurate definition of the natural history of chronic HBV infection not only sheds light on the pathogenesis of chronic hepatitis B but also helps determine the optimal timing for antiviral therapy to cure HBV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55. This manuscript reports the first nation-level prevalence estimates of chronic HBV by systemic literature review and also estimates the number of CHB patients on a national, regional, and global level.

  2. Lin CL, Kao JH. Perspectives and control of hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2015. doi:10.1016.

    Google Scholar 

  3. Tseng TC, Kao JH. Treating immune-tolerant hepatitis B. J Viral Hepat. 2015;22:77–84.

    Article  CAS  PubMed  Google Scholar 

  4. Kao, J-H. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015.

  5. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.

    Article  CAS  PubMed  Google Scholar 

  6. Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009;19:231–4.

    Article  PubMed  Google Scholar 

  7. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000;15(Suppl):E3–6.

    Article  PubMed  Google Scholar 

  8. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415–30.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–52.

    Article  PubMed  Google Scholar 

  10. Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology. 2007;132:2340–5.

    Article  PubMed  Google Scholar 

  11. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–29.

    Article  CAS  PubMed  Google Scholar 

  12. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61:1754–64. This paper provides a comprehensive review on how HBV interacts with the host innate and adaptive immunity during chronic HBV infection and how we can harness the immune response to potentially control HBV infection.

  13. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology. 2007;133:951–8.

    Article  CAS  PubMed  Google Scholar 

  14. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol. 2010;84:3454–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lavocat F, Deny P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, et al. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013;59:684–95.

    Article  CAS  PubMed  Google Scholar 

  16. Kennedy PT, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143:637–45. This paper challenges the conventional view of an immunotolerant state of young HBV carriers and demonstrates that children and young adults with chronic HBV infection have a less compromised HBV-specific immune profile than that observed in older patients.

  17. Bertoletti A, Hong M. Age-dependent immune events during HBV infection from birth to adulthood: an alternative interpretation. Front Immunol. 2014;5:441.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int. 2008;2:28–36.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol. 2003;39 Suppl 1:S160–3.

    Article  PubMed  Google Scholar 

  20. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.

    Article  CAS  PubMed  Google Scholar 

  21. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188–94.

    Article  CAS  PubMed  Google Scholar 

  22. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119(71):e79–16.

    Google Scholar 

  23. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15:133–43.

    Article  PubMed  Google Scholar 

  24. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141:517–25. 525 e511-512.

    Article  CAS  PubMed  Google Scholar 

  25. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.

    Article  PubMed  Google Scholar 

  26. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–34.

    Article  CAS  PubMed  Google Scholar 

  27. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–65.

    Article  CAS  PubMed  Google Scholar 

  28. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435–44.

    Article  PubMed  Google Scholar 

  29. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–68.

    Article  CAS  PubMed  Google Scholar 

  30. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–52.

    Article  PubMed  Google Scholar 

  31. Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57:84–90.

    Article  CAS  PubMed  Google Scholar 

  32. Shimakawa, Y, Lemoine, M, Njai, HF, Bottomley, C, Ndow, G, Goldin, RD et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2015. This is the first paper that reports the natural history of HBV infection in West Africa, where genotype E infection is prevalent.

  33. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387–92.

    CAS  PubMed  Google Scholar 

  34. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727–34.

    Article  CAS  PubMed  Google Scholar 

  35. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246–52.

    Article  CAS  PubMed  Google Scholar 

  36. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075–86.

    Article  CAS  PubMed  Google Scholar 

  37. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-Anti-HBe seroconversion. J Clin Microbiol. 2002;40:16–21.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395–401.

    Article  PubMed  Google Scholar 

  39. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.

    Article  CAS  PubMed  Google Scholar 

  40. Lin CL, Tseng TC, Kao JH. What can we learn from hepatitis B virus clinical cohorts? Liver Int : Off J Int Assoc Study Liver. 2015;35 Suppl 1:91–9.

    Article  CAS  Google Scholar 

  41. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694–701.

    Article  PubMed  Google Scholar 

  42. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–92.

    Article  PubMed  Google Scholar 

  43. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192–9.

    Article  CAS  PubMed  Google Scholar 

  44. Kim JH, Lee JH, Park SJ, Bae MH, Kim JH, do Kim Y, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepato-Gastroenterology. 2008;55:578–81.

    PubMed  Google Scholar 

  45. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–82.

    Article  PubMed  Google Scholar 

  46. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51:1531–7.

    Article  PubMed  Google Scholar 

  47. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012;55:68–76.

    Article  PubMed  Google Scholar 

  48. Hsu HY, Chang MH, Lee CY, Chen JS, Hsu HC, Chen DS. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology. 1992;15:382–6.

    Article  CAS  PubMed  Google Scholar 

  49. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res. 2010;108:21–72.

    Article  CAS  PubMed  Google Scholar 

  50. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273 e1261. This paper provides a comprehensive review on the risk factors of HCC, clinical outcomes, and disease burden based on epidemiologic studies and meta-analysis.

  51. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.

    Article  PubMed  Google Scholar 

  52. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    Article  CAS  PubMed  Google Scholar 

  53. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.

    Article  PubMed  Google Scholar 

  54. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2007;5:921–31.

    Article  Google Scholar 

  55. Marciano S, Galdame OA, Gadano AC. HBV genotype F: natural history and treatment. Antivir Ther. 2013;18:485–8.

    Article  PubMed  Google Scholar 

  56. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33:97–102. This review summarizes the evidence that the HBV genotype affects disease progression and compares the clinical and virological features among different HBV genotypes.

  57. Ni Y-H, Chang M-H, Wang K-J, Hsu H-Y, Chen H-L, Kao J-H, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127:1733–8.

    Article  CAS  PubMed  Google Scholar 

  58. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133:1452–7.

    Article  CAS  PubMed  Google Scholar 

  59. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002;123:1848–56.

    Article  PubMed  Google Scholar 

  60. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–9.

    Article  CAS  PubMed  Google Scholar 

  61. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lin, CL, and Kao, JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5.

  63. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 2009;6:453–62.

    Article  CAS  PubMed  Google Scholar 

  64. Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DK, Doutreloigne J, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J infect Dis. 2002;186:1335–8.

    Article  CAS  PubMed  Google Scholar 

  65. Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J Hepatol. 1998;28:915–22.

    Article  CAS  PubMed  Google Scholar 

  66. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 2003;38:619–28.

    Article  CAS  PubMed  Google Scholar 

  67. Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol. 2012;56:795–802.

    Article  CAS  PubMed  Google Scholar 

  68. Liu CJ, Chen PJ, Lai MY, Lin FY, Wang T, Kao JH, et al. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int : Off J Int Assoc Study Liver. 2006;26:949–55.

    Article  CAS  Google Scholar 

  69. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol: WJG. 2006;12:6620–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Tseng TC, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64(2):292–302. This paper demonstrates that quantitative measurement of HBV BCP mutation is more useful than qualitative measurement and may serve as a biomarker of liver cirrhosis 1 year after HBeAg seroconversion.

  71. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013;57:934–43.

    Article  CAS  PubMed  Google Scholar 

  72. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology. 2006;130:1153–68.

    Article  CAS  PubMed  Google Scholar 

  73. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133:1466–74.

    Article  CAS  PubMed  Google Scholar 

  74. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52:1232–41.

    Article  CAS  PubMed  Google Scholar 

  75. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–22.

    Article  CAS  PubMed  Google Scholar 

  76. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508–13.

    Article  CAS  PubMed  Google Scholar 

  77. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–90.

    Article  CAS  PubMed  Google Scholar 

  78. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis. 2012;205:54–63.

    Article  CAS  PubMed  Google Scholar 

  79. Tseng, TC, Liu, CJ, Yang, HC, Su, TH, Wang, CC, Chen, CL et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149 e1143; quiz e1113-1144. This paper demonstrates that, compared to HBV DNA levels, HBsAg levels in patients with low viral load can further stratify patients with high and low risks of HCC.

  80. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441–50. This paper reports that, in HBeAg-negative patients with low viral load, high HBsAg levels predict disease progression and HBsAg <1000 IU/mL with normal ALT helps define minimal risk of HBV carriers.

  81. Tseng TC, Liu CJ, Yang WT, Chen CL, Yang HC, Su TH, et al. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. J Gastroenterol Hepatol. 2014;29:1242–9.

    Article  CAS  PubMed  Google Scholar 

  82. Li A, Yuan Q, Huang Z, Fan J, Guo R, Lou B, et al. Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol: CVI. 2010;17:464–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013;62:182–4. This paper firstly demonstrates that total anti-HBc antibody levels are highly associated with ALT levels and can predict the antiviral treatment responses.

  84. Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine. 2014;93:e322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015;21:197–203.

    Article  CAS  PubMed  Google Scholar 

  86. Yuan Q, Song LW, Cavallone D, Moriconi F, Cherubini B, Colombatto P, et al. Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease. PLoS One. 2015;10:e0130209.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Fan, R, Sun, J, Yuan, Q, Xie, Q, Bai, X, Ning, Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan

    Hung-Chih Yang

  2. Graduate Institute of Clinical medicine, National Taiwan University College of Medicine, Taipei, Taiwan

    Hung-Chih Yang & Jia-Horng Kao

  3. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Hung-Chih Yang & Jia-Horng Kao

  4. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

    Jia-Horng Kao

Authors
  1. Hung-Chih Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia-Horng Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia-Horng Kao.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hepatitis B

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, HC., Kao, JH. Revisiting the Natural History of Chronic HBV Infection. Curr Hepatology Rep 15, 141–149 (2016). https://doi.org/10.1007/s11901-016-0304-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-016-0304-z

Keywords

Search

Navigation